Evidence map›Paper›PMID 35806075›Full record

ReviewInternational journal of molecular sciences2022

Molecular Basis Underlying the Therapeutic Potential of Vitamin D for the Treatment of Depression and Anxiety.

Bruna R Kouba, Anderson Camargo, Joana Gil-Mohapel, Ana Lúcia S Rodrigues

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 5 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. FIGO best practice recommendations for the mental health of women at menopausal age.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Bruna R KoubaCenter of Biological Sciences, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.
Anderson CamargoCenter of Biological Sciences, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.ORCID 0000-0002-1632-4865
Joana Gil-MohapelIsland Medical Program, Faculty of Medicine, University of British Columbia, Victoria, BC V8P 5C2, Canada.ORCID 0000-0003-4982-1662
Ana Lúcia S RodriguesCenter of Biological Sciences, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.ORCID 0000-0001-6285-8780
Universidade Federal de Santa Catarina · BRUniversity of British Columbia · CA

Funding

National Council for Scientific and Technological Development CNPq; #411143/2018-5 and #312215/2021-5University of Victoria (UVic, Victoria, BC, Canada) - São Paulo Research Foundation (FAPESP, São Paulo, SP, Brazil) SPRINT partnership UVic-FAPESP SPRINT 1/2018 Grant
6 · The paper itself

Abstract

Major depressive disorder and anxiety disorders are common and disabling conditions that affect millions of people worldwide. Despite being different disorders, symptoms of depression and anxiety frequently overlap in individuals, making them difficult to diagnose and treat adequately. Therefore, compounds capable of exerting beneficial effects against both disorders are of special interest. Noteworthily, vitamin D deficiency has been associated with an increased risk of developing depression and anxiety, and individuals with these psychiatric conditions have low serum levels of this vitamin. Indeed, in the last few years, vitamin D has gained attention for its many functions that go beyond its effects on calcium-phosphorus metabolism. Particularly, antioxidant, anti-inflammatory, pro-neurogenic, and neuromodulatory properties seem to contribute to its antidepressant and anxiolytic effects. Therefore, in this review, we highlight the main mechanisms that may underlie the potential antidepressant and anxiolytic effects of vitamin D. In addition, we discuss preclinical and clinical studies that support the therapeutic potential of this vitamin for the management of these disorders.

Indexed as

Anti-Anxiety AgentsMajor Depressive DisorderVitamin D DeficiencyAntidepressive AgentsAnxietyAnxiety DisordersDepressionHumansVitamin DVitaminsAnti-Anxiety AgentsAntidepressive AgentsVitamin DVitaminsanti-inflammatory effectanxietydepressionneuromodulatorpro-neurogenic effectvitamin D

Identifiers

PMID35806075
PMCPMC9266859
OpenAlexW4283524210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.